Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
RGLS's Cash to Debt is ranked higher than
72% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: 68.31 vs. RGLS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RGLS' s 10-Year Cash to Debt Range
Min: 1.76  Med: 8.86 Max: No Debt
Current: No Debt
Equity to Asset 0.88
RGLS's Equity to Asset is ranked higher than
76% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RGLS: 0.88 )
Ranked among companies with meaningful Equity to Asset only.
RGLS' s 10-Year Equity to Asset Range
Min: -1.26  Med: 0.72 Max: 0.89
Current: 0.88
-1.26
0.89
F-Score: 3
Z-Score: 11.93
M-Score: -2.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -414.25
RGLS's Operating margin (%) is ranked lower than
69% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -71.95 vs. RGLS: -414.25 )
Ranked among companies with meaningful Operating margin (%) only.
RGLS' s 10-Year Operating margin (%) Range
Min: -585.6  Med: -99.01 Max: -51.76
Current: -414.25
-585.6
-51.76
Net-margin (%) -506.06
RGLS's Net-margin (%) is ranked lower than
73% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: -68.66 vs. RGLS: -506.06 )
Ranked among companies with meaningful Net-margin (%) only.
RGLS' s 10-Year Net-margin (%) Range
Min: -739.08  Med: -137.07 Max: -55.13
Current: -506.06
-739.08
-55.13
ROE (%) -59.45
RGLS's ROE (%) is ranked lower than
67% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. RGLS: -59.45 )
Ranked among companies with meaningful ROE (%) only.
RGLS' s 10-Year ROE (%) Range
Min: -169.02  Med: -50.28 Max: -24
Current: -59.45
-169.02
-24
ROA (%) -47.90
RGLS's ROA (%) is ranked lower than
66% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: -26.75 vs. RGLS: -47.90 )
Ranked among companies with meaningful ROA (%) only.
RGLS' s 10-Year ROA (%) Range
Min: -38.49  Med: -29.62 Max: -16.48
Current: -47.9
-38.49
-16.48
ROC (Joel Greenblatt) (%) -1862.53
RGLS's ROC (Joel Greenblatt) (%) is ranked lower than
69% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: -365.20 vs. RGLS: -1862.53 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RGLS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1544.17  Med: -531.03 Max: -450.68
Current: -1862.53
-1544.17
-450.68
» RGLS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RGLS Guru Trades in

RGLS Guru Trades in

RGLS Guru Trades in

Q2 2015

RGLS Guru Trades in Q2 2015

Jim Simons 57,000 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with RGLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.23
RGLS's P/B is ranked higher than
62% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. RGLS: 3.23 )
Ranked among companies with meaningful P/B only.
RGLS' s 10-Year P/B Range
Min: 2.5  Med: 4.13 Max: 12.91
Current: 3.23
2.5
12.91
P/S 29.68
RGLS's P/S is ranked lower than
73% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.19 vs. RGLS: 29.68 )
Ranked among companies with meaningful P/S only.
RGLS' s 10-Year P/S Range
Min: 0.11  Med: 19.32 Max: 113.71
Current: 29.68
0.11
113.71
Current Ratio 9.91
RGLS's Current Ratio is ranked higher than
75% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.15 vs. RGLS: 9.91 )
Ranked among companies with meaningful Current Ratio only.
RGLS' s 10-Year Current Ratio Range
Min: 1.64  Med: 8.00 Max: 12.36
Current: 9.91
1.64
12.36
Quick Ratio 9.91
RGLS's Quick Ratio is ranked higher than
75% of the 833 Companies
in the Global Biotechnology industry.

( Industry Median: 4.01 vs. RGLS: 9.91 )
Ranked among companies with meaningful Quick Ratio only.
RGLS' s 10-Year Quick Ratio Range
Min: 1.64  Med: 8.00 Max: 12.36
Current: 9.91
1.64
12.36
Days Sales Outstanding 16.86
RGLS's Days Sales Outstanding is ranked higher than
87% of the 568 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. RGLS: 16.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
RGLS' s 10-Year Days Sales Outstanding Range
Min: 1.47  Med: 7.26 Max: 13.04
Current: 16.86
1.47
13.04

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.50
RGLS's Price/Net Cash is ranked higher than
77% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 7.71 vs. RGLS: 3.50 )
Ranked among companies with meaningful Price/Net Cash only.
RGLS' s 10-Year Price/Net Cash Range
Min: 3.66  Med: 4.72 Max: 8.92
Current: 3.5
3.66
8.92
Price/Net Current Asset Value 3.38
RGLS's Price/Net Current Asset Value is ranked higher than
77% of the 537 Companies
in the Global Biotechnology industry.

( Industry Median: 6.85 vs. RGLS: 3.38 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RGLS' s 10-Year Price/Net Current Asset Value Range
Min: 3.52  Med: 4.53 Max: 8.11
Current: 3.38
3.52
8.11
Price/Tangible Book 3.24
RGLS's Price/Tangible Book is ranked higher than
68% of the 693 Companies
in the Global Biotechnology industry.

( Industry Median: 5.31 vs. RGLS: 3.24 )
Ranked among companies with meaningful Price/Tangible Book only.
RGLS' s 10-Year Price/Tangible Book Range
Min: 3.34  Med: 4.30 Max: 7.38
Current: 3.24
3.34
7.38
Price/Median PS Value 1.58
RGLS's Price/Median PS Value is ranked lower than
68% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: 1.08 vs. RGLS: 1.58 )
Ranked among companies with meaningful Price/Median PS Value only.
RGLS' s 10-Year Price/Median PS Value Range
Min: 0.01  Med: 1.05 Max: 4.92
Current: 1.58
0.01
4.92
Earnings Yield (Greenblatt) (%) -23.27
RGLS's Earnings Yield (Greenblatt) (%) is ranked lower than
80% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. RGLS: -23.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RGLS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -31.81  Med: 0.00 Max: 0
Current: -23.27
-31.81
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 16 15 15
EPS($) -1.31 -1.66 -2.05
EPS without NRI($) -1.31 -1.66 -2.05

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:7RG.Germany,
Regulus Therapeutics Inc. was incorporated in the State of Delaware. It is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a broad range of diseases. The Company was formed in 2007 when Alnylam Pharmaceuticals, Inc., or Alnylam, and Isis Pharmaceuticals, Inc., or Isis, contributed significant intellectual property, know-how and financial and human capital to pursue the development of drugs targeting microRNAs pursuant to a license and collaboration agreement. microRNAs are recently discovered, naturally occurring ribonucleic acid, or RNA, molecules that play a critical role in regulating key biological pathways. Scientific research has shown the improper balance, or dysregulation, of microRNAs is directly linked to many diseases. The Company benefits substantially from the collective therapeutic RNA expertise of its founding companies, including established proprietary oligonucleotide-based technologies, and broad and dominant intellectual property estates specific to chemically modified oligonucleotides. The Company has exclusive rights to over 900 patents and patent applications pertaining to oligonucleotide modifications, conjugates, and design patterns, all for use in targeting microRNA for therapeutic applications. The microRNA therapeutics are oligonucleotide medicines that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat human disease. It is currently optimizing anti-miRs targeting miR-21, miR-122, miR-33 and miR-10b for development candidate selection. It has established strategic alliances with AstraZeneca, GSK and Sanofi and it will continue to seek partners who can bring therapeutic expertise, development and commercialization capabilities and funding to allow it to maximize the potential of its microRNA product platform. Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of products such as those it is developing.
» More Articles for RGLS

Headlines

Articles On GuruFocus.com
buffet May 31 2015 
buffet May 31 2015 
Weekly CEO Sells Highlight: Hovnanian Enterprises Inc, Regulus Therapeutics Inc, Monster Beverage Co Apr 27 2015 
Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment, Dave & Buster's Entertainment (P Apr 08 2015 
This Week’s Pharma Highlights Mar 19 2015 
cg Feb 16 2015 
Weekly CEO Sells Highlight: Kimberly-Clark Corp, Regulus Therapeutics Inc, Prologis Inc, and Adobe S Feb 01 2015 

More From Other Websites
5 Stocks Under $10 Set to Soar Aug 27 2015
Regulus Appoints Michael Huang, M.D. as Vice President, Clinical Development Aug 25 2015
Regulus Appoints Michael Huang, M.D. as Vice President, Clinical Development Aug 25 2015
REGULUS THERAPEUTICS INC. Financials Aug 13 2015
Biotech Stock Mailbag: Controversial Stocks Revisited Aug 07 2015
Regulus to Present at the 2015 Wedbush PacGrow Healthcare Conference Aug 06 2015
Regulus to Present at the 2015 Wedbush PacGrow Healthcare Conference Aug 06 2015
REGULUS THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report Aug 05 2015
Edited Transcript of RGLS earnings conference call or presentation 4-Aug-15 9:00pm GMT Aug 04 2015
Regulus reports 2Q loss Aug 04 2015
Regulus reports 2Q loss Aug 04 2015
Regulus Therapeutics Inc Earnings Call scheduled for 5:00 pm ET today Aug 04 2015
REGULUS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 04 2015
Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights Aug 04 2015
Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights Aug 04 2015
Q2 2015 Regulus Therapeutics Inc Earnings Release - After Market Close Aug 04 2015
Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call Jul 28 2015
Regulus Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call Jul 28 2015
RA Capital Is Expecting A Breakthrough Cancer Drug From This Biotech Jun 29 2015
REGULUS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers Jun 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK